Melbourne, Australia-based Telix Pharmaceuticals (NASDAQ:TLX) reported unaudited financial and operational highlights for the full year and fourth quarter ended December 31, 2025.
Group revenue for fiscal 2025 reached approximately $804 million (A$1.2 billion), aligning with the company's upgraded guidance range of $800–820 million.
Fourth-quarter revenue totaled $208 million, reflecting a 46% increase compared with the year-ago period.
Growth was primarily driven by the Precision Medicine business, which generated approximately $161 million in Q4 revenue.
The strong performance was supported by the successful U.S. commercial launch of Gozellix (gallium-68 gozetotide) following Centers for Medicare & Medicaid Services reimbursement effective October 1, 2025.
The company also achieved several key program and commercial milestones during 2025, including first patient dosing in multiple therapeutic and imaging clinical trials such as ProstACT Part 2, SOLACE, BiPASS, and the Japan TLX591-Px study.
Meanwhile, China’s National Medical Products Administration accepted the new drug application for TLX591-Px, while Telix maintained approximately 55% national market share for PSMA-PET imaging in Australia.
Additionally, the company entered a strategic collaboration with Varian to explore combination approaches with external beam radiation therapy.